KLRS KALARIS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, KALARIS THERAPEUTICS INC reported revenue of n/a, net income of −$11.5M and diluted EPS of −$0.48; for the fiscal year ended December 2025 revenue was n/a.
KLRS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$46.2M, net income −$43.4M (margin n/a), EPS −$2.85
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$51.7M, net income −$69.2M (margin n/a), EPS −$51.77
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$200M, net income −$190M (margin n/a), EPS −$42.09
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$171M, net income −$169M (margin n/a), EPS −$2.20
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$170M, net income −$172M (margin n/a), EPS −$2.74
KLRS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$11.5M, EPS −$0.48
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.9M, EPS −$0.46
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$9.99M, EPS $0.92
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.9M, EPS −$0.64
- Quarter ended Jun 30, 2025: revenue n/a, net income −$11.4M, EPS −$0.61
- Quarter ended Mar 31, 2025: revenue n/a, net income −$10.2M, EPS −$2.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$22.0M, EPS −$16.75
- Quarter ended Sep 30, 2024: revenue n/a, net income −$38.1M, EPS −$28.16
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.65M, EPS −$4.26
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.41M, EPS −$2.60
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$59.7M, EPS −$40.78
- Quarter ended Sep 30, 2023: revenue n/a, net income −$44.3M, EPS −$0.39
- Quarter ended Jun 30, 2023: revenue n/a, net income −$45.3M, EPS −$0.48
- Quarter ended Mar 31, 2023: revenue n/a, net income −$41.2M, EPS −$0.44
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$38.1M, EPS −$0.32
- Quarter ended Sep 30, 2022: revenue n/a, net income −$42.1M, EPS −$0.50
- Quarter ended Jun 30, 2022: revenue n/a, net income −$44.6M, EPS −$0.69
- Quarter ended Mar 31, 2022: revenue n/a, net income −$43.9M, EPS −$0.69
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$57.9M, EPS −$0.92
- Quarter ended Sep 30, 2021: revenue n/a, net income −$45.5M, EPS −$0.72
KLRS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$38.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$20.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$124M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$142M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$106M, share buybacks n/a
KLRS balance sheet
- Jun 30, 2026: cash $43.2M, total assets $99.5M, total liabilities $41.9M, shareholders' equity $57.7M
- Mar 31, 2026: cash $34.4M, total assets $110M, total liabilities $41.2M, shareholders' equity $68.6M
- Dec 31, 2025: cash $98.1M, total assets $122M, total liabilities $42.9M, shareholders' equity $78.8M
- Sep 30, 2025: cash $42.4M, total assets $81.2M, total liabilities $39.3M, shareholders' equity $41.9M
- Jun 30, 2025: cash $88.4M, total assets $92.8M, total liabilities $39.7M, shareholders' equity $53.1M
- Mar 31, 2025: cash $101M, total assets $103M, total liabilities $39.2M, shareholders' equity $63.9M
- Dec 31, 2024: cash $1.64M, total assets $6.16M, total liabilities $56.8M, shareholders' equity −$96.6M
- Sep 30, 2024: cash $1.91M, total assets $123M, total liabilities $1.41M, shareholders' equity −$89.4M
Is KLRS profitable?
No. KALARIS THERAPEUTICS INC lost $44.3M over the last four quarters.
What is KLRS's EPS?
Diluted earnings per share over the last four quarters were −$0.66; −$0.48 in the latest quarter.